Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday

Core Insights - Corcept Therapeutics received FDA approval for its drug Lifyorli, which is to be used in combination with nab-paclitaxel for treating platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer, leading to a nearly 20% increase in its stock value [1][2][5] FDA Approval - The FDA's approval was based on positive results from the Rosella trial, which involved 381 patients receiving either the combination therapy or Lifyorli alone [4] Company Strategy - Corcept focuses on therapies that modulate cortisol, the "stress hormone," and plans to continue exploring this treatment strategy, as indicated by CEO Joseph Belanoff [5] Market Potential - The approval of Lifyorli not only provides a high-potential product in the cancer segment but also validates Corcept's unique focus on cortisol modulation, suggesting potential for more approvals in the future [5]